The overexpression of the chemokine receptor 4 (CXCR4) in different epithelial, mesenchymal, and hematopoietic cancers makes CXCR4 an attractive diagnostic and therapeutic target. This evidence concerns the gene CXCR4 and hematopoietic and lymphoid cell neoplasm.